Picamilon

Picamilon, also spelled pikamilon, is the sodium salt of N-nicotinoyl-gamma-aminobutyric acid, a synthetic molecule that chemically links niacin (nicotinic acid, vitamin B3) to the inhibitory neurotransmitter GABA through an amide bond ^[2][4]. This conjugate design is the compound's defining feature: plain GABA does not efficiently cross the blood-brain barrier, but attaching the lipophilic nicotinoyl group creates a prodrug that can enter the brain and then be hydrolyzed to release both GABA and niacin at its target ^[4]. It belongs to the broader family of GABA analogues that also includes phenibut and the drug baclofen ^[1].

Picamilon was developed in the Soviet Union and introduced into Russian clinical practice as a cerebrovascular and nootropic medicine, and it is documented in the pharmacology literature as a cerebrovascular preparation ^[2]. In the former Soviet states it has been prescribed for cerebrovascular disorders, for conditions involving reduced cerebral blood flow, and as a mild anxiolytic and asthenia treatment, and its cerebral-circulation effects have been documented in animal studies showing increased cortical blood supply and dilation of pial arterioles ^[2][3]. Human research from Russian centers has examined picamilon in applied settings, such as aiding cerebral hemodynamic recovery in swimmers with a dysadaptation syndrome ^[7].

Outside Russia picamilon is not an approved medicine. In the United States the Food and Drug Administration has determined that it does not qualify as a dietary ingredient, yet it has been sold directly to consumers as a nootropic supplement, and analytical surveys have found it in commercial products at widely varying amounts, from a few milligrams to several hundred milligrams per serving ^[1][6]. A modern regulatory-toxicology screen of picamilon against 50 safety-related receptors, ion channels, enzymes, and transporters found essentially no binding, underscoring that its activity depends on being metabolized to GABA and niacin rather than on the intact molecule itself ^[1]. It is most often encountered as a crystalline powder or in capsules under the names picamilon or pikamilon ^[1][6].

Avoid picamilon if you're hypersensitive to niacin or GABA, or if you have severe liver or kidney trouble. It can add to CNS depressants like alcohol and benzodiazepines. Worth knowing: in 2015 the FDA sent a warning letter saying picamilon doesn't count as a dietary ingredient, which pulled it from a lot of supplement shelves in the US. It rarely causes dependence, but stopping abruptly after long high-dose use can bring a bout of rebound anxiety.

Picamilon is a niacin-GABA conjugate that hydrolyzes to nicotinic acid and GABA, and it has no formal drug-interaction studies. Any concern derives from the niacin moiety: nicotinic acid is a vasodilator, so an additive hypotensive or flushing effect with antihypertensives or other vasodilators is theoretical rather than documented for picamilon specifically. There is no established CYP-mediated or clinically characterized interaction data for the intact compound. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Picamilon, chemically N-nicotinoyl-GABA, was created in the Soviet Union at the All-Union Vitamin Research Institute, where researchers set out to solve a specific pharmacological problem: the neurotransmitter GABA cannot readily cross the blood-brain barrier, limiting its usefulness as a calming agent. Their solution, developed around 1969, was to bond a molecule of GABA to niacin, producing a lipophilic conjugate that could carry GABA into the central nervous system and then be cleaved to release both components.

The compound was subsequently developed as a cerebrovascular and anxiolytic medicine and was approved for clinical use in Russia in the mid-1980s, where it became a mainstay of neurology for conditions involving impaired cerebral circulation, anxiety, and asthenia. Much of the foundational research was conducted and published within the Russian scientific literature, and picamilon has never been approved as a drug in the United States, where it is instead sold as a dietary-style supplement and nootropic. Its unusual two-in-one prodrug design remains its defining scientific feature.

Picamilon enjoys a favorable reputation as a gentle, non-sedating way to combine mild relaxation with improved blood flow to the brain, a pairing that distinguishes it from heavier GABAergic agents. Russian clinical experience accumulated over several decades supports its use as a cerebrovascular agent, and animal studies document genuine dilation of the small pial vessels and increases in cerebral blood flow that appear to depend on GABA receptor signaling.

Enthusiasts in the nootropic community appreciate that it tends to calm without the grogginess or dependence associated with stronger anxiolytics, and modern safety screening found the intact molecule to be largely inert until metabolized, consistent with its prodrug design. The honest caveats are that most of the rigorous evidence comes from older Russian-language research rather than large Western trials, that it is not an approved medicine in many countries, and that the niacin it releases can cause a flushing sensation at higher doses. For those seeking a mild, well-characterized calming and circulatory aid, it remains an intriguing and well-documented compound.